Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07128316 · ClinicalTrials.gov registry record · NA

LASIK Using Contoura With Phorcides vs. iDesign

A NA study of Myopia and Astigmatism, sponsored by 59th Medical Wing.

Active
Registry status
NA
Development phase
63
Enrollment target
1
Study location

NCT07128316: Active NA study of Myopia and Astigmatism, sponsored by 59th Medical Wing.

NCT07128316 is a NA study of Myopia and Astigmatism that is active but no longer recruiting, run by 59th Medical Wing. The registered enrollment target is 63 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07128316, a NA study of Myopia and Astigmatism, is active but no longer recruiting, sponsored by 59th Medical Wing.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
63 participants
Enrollment target
1
Study location

Study Summary

Participants will undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia.

Primary Outcome

Post-operative uncorrected visual acuity of 20/16 or better measure with ETDRS chart; unit = percentage eyes with Uncorrected Visual Acuity.

Conditions Studied

Interventions

  • DEVICE Contoura Topolyzer with Phorcides
  • DEVICE iDesign

Study Locations (1)

Texas

  • Joint Warfighter Refractive Surgery Center at WHASC - San Antonio

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2023-09-11
Est. Completion 2025-12-15
Phase NA
59th Medical Wing

20 total trials

What the registry record for NCT07128316 still lists

NCT07128316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower).

The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Contoura Topolyzer with Phorcides is the first listed.

NCT07128316 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07128316 about?

NCT07128316 is a clinical study titled "LASIK Using Contoura With Phorcides vs. iDesign". Participants will undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia.

What is the current status of trial NCT07128316?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 63 participants. The study started on 2023-09-11. Estimated completion is 2025-12-15.

What conditions does trial NCT07128316 study?

This clinical trial studies the following conditions: Myopia, Astigmatism.

What interventions are being tested in trial NCT07128316?

The interventions under investigation include: Contoura Topolyzer with Phorcides (DEVICE), iDesign (DEVICE).

Who is sponsoring clinical trial NCT07128316?

This trial is sponsored by 59th Medical Wing, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07128316 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07128316's enrollment target sits among peer trials

63 58th of 90 higher than 32 of 90 other Myopia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03383575 · 63 participants · Phase 2

    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • NCT04870944 · 63 participants · Phase 1

    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • NCT05031897 · 63 participants · Phase 2

    Two Step Haplo With Radiation Conditioning

  • NCT05312671 · 63 participants · Phase 2

    Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07128316, the US trial registry maintained by the National Library of Medicine. NCT07128316 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.